Close Menu

NIA

The Phase 2 grant is for work the company is doing to analyze the proteomic responses of immune cells in patients with Alzheimer's and related conditions.

The blood-based test is designed to detect changes in levels of microRNAs that are enriched in specific brain regions affected by Alzheimer's disease.

In Nucleic Acids Research this week: approach to generate chromatin interaction networks, signature of cellular senescence, and more.

The findings implicated immune response, lipid metabolism, tau binding proteins, and amyloid precursor protein metabolism pathways in disease risk.

New Mice for the Job

Researchers have developed a new Alzheimer's disease mouse model with greater genetic diversity.

The UPenn team will collect genetic information from outside patient cohorts, reorganize it in a streamlined process, and provide a database for downstream studies.

Both a genome-wide association study and a rare variant burden analysis homed in on a role for KIF5A mutations in amyotrophic lateral sclerosis.

A meta-analysis based on genotyping data for more than 400,000 people with or without the disease led to 17 new risk loci mined for candidate genes

The initiative was launched to conduct a large-scale study of cognitive impairment and Alzheimer's disease to advance the discovery of biomarkers of the conditions.

UPenn will establish the Coordinating Center for Genetics and Genomics of Alzheimer's Disease in collaboration with five other institutions.

Pages

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.